Updates in the Treatment of Lymphoma

Treatment decisions and management of indolent non-Hodgkin lymphomas are continually evolving and the use of novel targeted therapy, antibodies, and other new therapies are increasing in clinical practice. The timing and order of when to use these agents is debated frequently. This presentation will help guide nurses in the use of novel agents, the timing of those agents, and the treatment when a patient has progressed after first-line therapy. New agents will be discussed, including administration information, side effects, and helpful patient education information for nursing.

Target Audience

This program is designed to meet the educational needs of oncology nurses who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss the treatment of chronic lymphocytic leukemia (CLL) in the 2nd and 3rd line setting.
  • Discuss treatment of follicular lymphoma (FL) for 2nd/3rd line treatment based on disease burden/performance status.
  • Discuss emerging therapies for mantle cell lymphoma (MCL), including immunotherapy and cellular therapy.
Additional information

This activity is supported by educational grants from:

  • AstraZeneca
  • Epizyme Inc.
  • Genentech, a member of the Roche Group
  • Novartis
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Pfizer Inc.
Course summary
Available credit: 
  • 0.75 ANCC contact hours
    • 0.75 ANCC Pharmacology Contact Hours
  • 0.75 Participation
Course opens: 
Course expires: 

Jessica Shelly, CRNP, APRN
Mayo Clinic Cancer Center


NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 


Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

Presenting Faculty

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Jessica Shelly, CRNP, APRN


The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Colleen Erb, MSN, RN, AOCNP

NCCN Staff Disclosures 

The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Crystal Denlinger, MD, FACP
Agios, Inc.: Grant/Research Support
Amgen Inc.: Grant/Research Support
Astellas Pharma US, Inc.: Scientific Advisor
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BeiGene: Scientific Advisor; Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Scientific Advisor; Grant/Research Support
Genmab: Grant/Research Support
MacroGenics: Grant/Research Support
MedImmune Inc: Grant/Research Support
Merck & Co., Inc.: Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor
Zymeworks: Scientific Advisor; Grant/Research Support

Samantha L. Tamburro, RN, BSN, CPON
Flatiron Health, Inc.: Salary

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this educational activity for a maximum of 0.75 contact hour, 0.75 of which are pharmacotherapeutic contact hours.

Available Credit

  • 0.75 ANCC contact hours
    • 0.75 ANCC Pharmacology Contact Hours
  • 0.75 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing